Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory compliance

InterCure Regains Nasdaq Minimum Bid Compliance

Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 09, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The confirmation removes the immediate threat of delisting, which could have severely impacted InterCure's liquidity and access to capital. The stock closed at $5.39 on September 8, 2026, well above the $1.00 minimum, indicating investor confidence in the company's continued listing.

cannabis pharmaceutical

InterCure Ltd., an Israeli cannabis company trading on Nasdaq under the ticker INCR, received confirmation on September 8, 2026, from Nasdaq that it had regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)). This followed a period of non-compliance that began when Nasdaq notified the company on February 25, 2026, that its share price had closed below $1.00 for 30 consecutive business days. InterCure was granted a 180-day compliance period expiring August 24, 2026. After failing to regain compliance by that deadline, Nasdaq issued a delisting notice on September 1, 2026. However, the company's shares subsequently traded at or above $1.00 for ten consecutive business days from August 24 through September 4, 2026, leading Nasdaq to confirm compliance and close the matter. This allows InterCure to continue trading on The Nasdaq Global Market, preserving its access to U.S. capital markets and investor visibility.

100 InterCure regained compliance Nasdaq
100 Nasdaq issued delisting notice InterCure
stock
InterCure is the subject of the compliance action; regaining compliance avoids delisting and supports its continued trading on Nasdaq, positively affecting its market position and investor confidence.
Importance 100.0 Sentiment 40.0
exch
Nasdaq is the exchange that issued the delisting notice and later confirmed compliance; its regulatory actions directly determine InterCure's listing status.
Importance 80.0 Sentiment 0.0
subs
InterCure — Canndoc, InterCure's wholly owned subsidiary and Israel's largest licensed cannabis producer, benefits indirectly from the parent company's continued Nasdaq listing, which supports its operations and growth.
Importance 30.0 Sentiment 40.0
cnt
Israel is the home country of InterCure and InterCure — Canndoc; the event reflects on the Israeli cannabis industry's access to international capital markets.
Importance 20.0 Sentiment 0.0
Nasdaq related ↔ Israel
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.